ER vs. IR [Design Issues]

posted by Dr_Dan  – 2019-12-19 08:01 (510 d 19:04 ago) – Posting: # 21004
Views: 2,110

Hi Helmut
your statement only holds true in your example with different strengths. If you have only one or the highest IR strength then my statement applies. The once daily (or 8 h) dosing of the ER formulation does not have to mimicry the performance of the multiple dosing of the IR formulation if you can show that there is a well-defined therapeutic window in terms of safety and efficacy and the rate of input is known not to influence the safety and efficacy profile or the risk for tolerance development.
KR
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

Activity
 Admin contact
21,457 posts in 4,485 threads, 1,512 registered users;
online 11 (0 registered, 11 guests [including 3 identified bots]).
Forum time: Thursday 03:06 UTC (Europe/Vienna)

Nothing in the world is more dangerous
than sincere ignorance
and conscientious stupidity.    Martin Luther King, Jr.

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5